摘要随着人类基因组测序、生物大数据信息分析、分子病理检测和人工智能辅助病理诊断等技术进步及其应用，临床医学发展迈向精准诊疗时代。这一时代背景下，传统诊断病理学迎来前所未有的历史机遇，正在向“下一代诊断病理学（next-generation diagnostic pathology）”迈进。下一代诊断病理学以病理形态和临床信息为诊断基础，以分子检测与生物信息分析、智慧制样与流程质控、智能诊断与远程会诊、病灶活体可视化与“无创”病理诊断等创新前沿交叉技术为主要特征，以多组学和跨尺度整合诊断为病理报告内容，实现对疾病的“最后诊断”，并预测疾病演进和结局、建议治疗方案和评估治疗反应，形成新的疾病诊断“金标准”。未来，需要激发病理学科创新活力，加快下一代诊断病理学成熟和应用，重塑病理学科理论和技术体系，发挥诊断病理学在疾病“防、诊、治、养”等过程中的重要作用，促进临床医学进一步发展，服务健康中国战略。

abstractsWith the technological progresses and applications of human genome sequencing, bioinformatics analysis and data mining, and molecular pathology and artificial intelligence-assisted pathological diagnosis, the development of clinical medicine is moving towards the era of precision diagnosis and treatment. In the context of this era, the traditional diagnostic pathology is facing unprecedented opportunities and challenges in our history and is striving towards the "next-generation diagnostic pathology" (NGDP). NGDP is based on histomorphology and clinical data, and characterized by the combination of molecular detection and bioinformatics analysis, intelligent sampling and process quality control, intelligent diagnosis and remote consultation, lesion visualization and "non-invasive" pathology as well as other innovative cutting edge interdisciplinary technologies. The NGDP reports will include the results from multi-omics and cross-scale integrated diagnosis for final diagnosis. NGDP will also be applied for predicting disease progression and outcomes, and determining optional therapeutics as well as assessing treatment responses, so that a novel "golden standard" of disease diagnosis can be established. In the near fature, it is necessary to stimulate the innovative vitality of pathology disciplines, accelerate the maturity and application for NGDP, update the theory and technical system of pathology, and perform its important applicable role in the prevention, diagnosis, treatment of diseases so that the futher development of clinical medicine will be promoted and the strategy for maintenance of being healthy in China will be served.